Introduction
Understanding clinical variants in genomics isn’t just for specialists anymore—it’s a growing necessity across healthcare and research. With genetic data playing a larger role in diagnostics and treatment decisions, grasping the basics of variant interpretation has become essential. This article breaks down the core concepts and methods you need to know.
What is Variant Interpretation?
Variant interpretation is the process of analyzing changes in DNA sequences, often referred to as variants, to determine their potential clinical significance. This involves assessing whether a particular genetic alteration is benign (not harmful), disease-causing (pathogenic), or of uncertain significance.
The primary goal is to understand how these changes might influence an individual’s health, disease risk, or treatment response. This process is foundational in clinical genomics as it bridges the gap between raw genetic data and actionable clinical insights, enabling targeted interventions and personalized care.
To streamline this process, platforms like omnomicsNGS integrate and automate variant interpretation workflows, reducing manual workload and improving speed and accuracy. By leveraging such tools, diagnostic laboratories and clinical researchers can process raw sequencing data and receive annotated, prioritized output that highlights clinically relevant variants.
A critical aspect of variant interpretation is the integration of comprehensive annotation data. Databases like ClinVar and CIViC provide curated information on variant-disease associations, functional effects, and population-level frequency data, refining classification and ensuring informed clinical relevance.
Additionally, adhering to industry standards such as ACMG, AMP, ASCO, and CAP guidelines ensures credibility and reliability, making variant interpretation a robust and clinically impactful process.
Why is Clinical Variant Interpretation Important?
Clinical variant interpretation holds immense significance in advancing precision medicine and improving patient care. By providing insights into the genetic basis of diseases, this process enables the development of tailored treatments.
For example, interpreting pathogenic variants can guide healthcare providers in selecting targeted therapies that address the underlying genetic cause instead of relying on generalized treatment approaches. This personalized approach can lead to better treatment efficacy, fewer side effects, and improved overall outcomes.
Adhering to established guidelines is another critical aspect of clinical variant interpretation. Frameworks like those from the American College of Medical Genetics (ACMG), Association for Molecular Pathology (AMP), American Society of Clinical Oncology (ASCO), and College of American Pathologists (CAP) provide standardized methodologies for classifying and interpreting genetic variants.
Compliance with these guidelines ensures that reports are both reliable and credible, fostering trust among healthcare providers and patients. Standardized protocols also minimize variability in interpretation across laboratories, reducing the risk of misclassification.
Handling patient data securely and in compliance with regulations is equally important. Genetic information is highly sensitive, and mishandling it can have serious ethical and legal consequences.
Regulations such as the General Data Protection Regulation (GDPR), Health Insurance Portability and Accountability Act (HIPAA), and In Vitro Diagnostic Regulation (IVDR) establish robust frameworks for protecting patient data. Adhering to these laws safeguards patient privacy while ensuring that data is handled responsibly. This level of diligence is important for maintaining patient trust and supporting the ethical advancement of genomic medicine.
Key Principles of Variant Analysis
Accurate and effective clinical variant analysis relies on a set of foundational principles that guide the interpretation process. These principles ensure that genetic variants are classified correctly, minimizing misinterpretation and its potential impact on patient care.
One key principle is understanding the established categories of pathogenicity. Variants are classified into five groups: benign, likely benign, uncertain significance (VUS), likely pathogenic, and pathogenic. These classifications depend on the strength of evidence supporting the variant’s relationship to disease.
For example, pathogenic variants (Class 5) are strongly associated with a disease and are supported by both functional and clinical evidence, whereas VUS (Class 3) requires further investigation because of insufficient or conflicting data.
Allele frequency in population databases plays a significant role in assessing variant rarity. Data from resources like gnomAD or the 1,000 Genomes Project help determine whether a variant is too common in the general population to be linked to a rare genetic disorder.
For example, generally, a variant with a frequency exceeding 5% in healthy individuals is typically classified as benign. However, pathogenic variants involved in certain diseases like Cystic Fibrosis can be found at higher frequencies in different populations. Inheritance patterns also provide critical context in variant analysis. Understanding whether a condition follows an autosomal dominant, autosomal recessive, or X-linked inheritance pattern helps assess whether a variant aligns with the observed family history or clinical features.
For example, a variant in a gene associated with an autosomal recessive condition has to typically be present in both copies (homozygous) for the phenotype to manifest, whereas a single pathogenic allele might suffice in autosomal dominant conditions.
. In addition, many computational tools can be utilized to assess the likelihood of a variant causing disruption of protein function, splicing, or other critical processes. While these tools provide valuable insights, their predictions require validation through experimental evidence or additional supporting data to strengthen confidence in the interpretation.
Methodologies for Clinical Variant Interpretation
1. Data Collection and Quality Assessment
Accurate clinical variant interpretation begins with high-quality data collection and robust quality assessment. Without reliable inputs, the downstream analysis risks being flawed, leading to incorrect conclusions and potentially harmful clinical decisions. To ensure a strong foundation, one should prioritize three critical aspects during this initial phase.
First, gather comprehensive patient information, which includes clinical history, genetic reports, and family data. These elements provide essential context for interpreting genetic variants. Clinical history helps correlate observed symptoms with potential genetic causes.
Genetic reports identify known or suspected variants, while family history can reveal inheritance patterns or segregating mutations. Together, these datasets establish a baseline for assessing the variant’s clinical relevance.
Second, utilize automated systems like omnomicsQ to streamline quality assurance processes. These tools enable real-time monitoring, ensuring the integrity of sequencing data throughout the analysis. These systems can flag inconsistencies, detect sample contamination, or identify technical artifacts, significantly reducing the risk of errors. By integrating these technologies into the workflow, high standards of data quality can be maintained while improving the efficiency.
Lastly, compliance with recognized standards, such as ISO 13485, governs the quality management systems for medical devices. Adhering to these standards is important for obtaining IVDR certification, a requirement for laboratories operating within Europe. Compliance not only guarantees a systematic approach to quality but also aligns the processes with international best practices. This is important for maintaining credibility and ensuring the reliability of your findings in clinical and regulatory contexts.
2. Database Utilization
Genomic databases play an essential role in supporting clinical variant interpretation by providing a wealth of information on genetic variants. Two widely used resources are ClinVar and gnomAD.
ClinVar is a publicly accessible database that collects reports of genetic variants and their clinical significance. It allows you to cross-reference a variant with prior classifications, literature citations, and supporting evidence, helping to build a more comprehensive understanding of its potential impact on health.
gnomAD, on the other hand, aggregates population-level data from large-scale sequencing projects. By examining the frequency of a variant in diverse populations, you can assess whether it is rare enough to be associated with a disease or common enough to likely be benign.
These databases enable you to combine statistical, clinical, and population-level data for more informed variant interpretations.
One critical aspect of database utilization is the need for automated re-evaluation of stored data. The genomic field evolves rapidly, with new studies and findings that can influence variant classification.
Without periodic reevaluation, previously unclassified or misclassified variants might remain static in their outdated state. Automated systems can help ensure that your variant interpretations remain aligned with the latest scientific evidence by systematically integrating updates from databases like ClinVar. This process reduces the risk of misinterpretation and improves diagnostic accuracy.
3. Computational Predictions
Computational tools play a key role in predicting the potential impact of genetic variants, particularly when experimental validation is not immediately available. Tools used for in silico predictions analyze how amino acid changes caused by genetic variants might affect protein structure or function.
For example, some tools evaluate the evolutionary conservation of amino acid residues across species, predicting whether a substitution is likely to be deleterious. Others integrate structural and sequence-based information to assess the likelihood that a variant will disrupt protein function. While these tools are not definitive on their own, they provide an important first step in prioritizing variants for further investigation.
Platforms like omnomicsNGS streamline this process by integrating computational predictions with multi-level data filtering strategies. By combining information from multiple sources—such as population databases, disease-specific datasets, and in silico predictions—tools like these systematically narrow down the list of variants to those most likely to be clinically relevant.
For instance, excluding variants found at high frequencies in large population datasets like gnomAD reduces the chance of falsely associating common polymorphisms with disease. This approach, combined with computational predictions, ensures a more focused and reliable analysis, allowing you to allocate resources effectively for downstream functional validation or clinical interpretation.
4. Functional Assays
Functional assays are laboratory-based methods designed to validate the biological impact of genetic variants. These experiments directly assess how a variant affects the function of a gene or protein, providing evidence beyond computational predictions or statistical correlations.
Functional assays evaluate processes such as protein stability, enzymatic activity, splicing efficiency, or cellular signaling pathways. Results from these tests help determine whether a variant contributes to disease or is benign, offering critical insights when other lines of evidence are inconclusive.
For example, splicing assays can reveal whether a variant disrupts normal RNA processing, while enzyme activity tests can measure functional impairment caused by amino acid changes.
Cross-laboratory standardization is important to ensure consistency and reliability in functional assay results. Participation in external quality assessment (EQA) programs, such as those organized by the European Molecular Genetics Quality Network (EMQN) and Genomics Quality Assessment (GenQA), plays a key role in promoting standardized practices and quality assurance. These programs evaluate laboratory performance in running functional assays, ensuring reproducibility and comparability of results across institutions.
Adherence to such programs, alongside compliance with international standards like ISO 13485, ensures that functional assay data used in clinical variant interpretation is credible and reliable.
5. Clinical Guidelines and Classification
Established clinical guidelines and classification systems are key tools in interpreting genetic variants with consistency and accuracy. One widely adopted framework is the ACMG-AMP guidelines, which classify variants into five categories: pathogenic, likely pathogenic, uncertain significance (VUS), likely benign, and benign.
These classifications rely on a structured evaluation of evidence, including population frequency data, computational predictions, functional studies, and genotype-phenotype correlations. By providing specific criteria for each category, the ACMG-AMP guidelines help ensure a standardized approach to variant interpretation across laboratories and clinicians.
In addition to manual interpretation, tools like omnomicsV support automated validation of variant classifications. These tools are particularly useful for ensuring compliance with regulatory standards, such as ISO 15189 accreditation.
By integrating the ACMG-AMP criteria into their algorithms, they enable faster, more consistent variant evaluations while reducing the risk of human error. This automation supports scalability in clinical genomics and improves adherence to best practices.
6. Genotype-Phenotype Correlation
Genotype-phenotype correlation is central to clinical variant interpretation. It involves linking genetic variants (genotype) to observable traits, conditions, or symptoms (phenotype). This relationship is important for understanding how specific mutations influence health outcomes, guiding diagnosis, and treatment planning.
For example, identifying a pathogenic variant in the SCN1A gene helps establish its connection to Dravet syndrome, a severe epileptic encephalopathy. However, this process requires careful evaluation, as not all variants directly result in a clinical phenotype. The context, including other genetic factors and environmental influences, often shapes the observed manifestation.
To ensure accuracy in genotype-phenotype correlation, laboratories rely on standardized protocols and performance reviews. These include:
- Adherence to clinical guidelines, such as those published by the American College of Medical Genetics (ACMG), which provide structured algorithms for variant interpretation.
- Accreditation frameworks like ISO 15189 and participation in external quality assurance programs (e.g., UKNEQAS) to maintain high analytical and interpretative standards.
- Ongoing monitoring of performance metrics through proficiency testing and inter-laboratory comparisons to identify and address discrepancies.
Such frameworks help reduce errors in variant classification. For example, in a notable legal case, a laboratory’s misclassification of an SCN1A variant as a “variant of unknown significance” (VUS) instead of “pathogenic” led to inappropriate treatment and severe patient harm.
The variant, classified in scientific literature as disease-causing at the time, was overlooked because of insufficient protocol adherence. This underscores the need for strict validation and re-evaluation processes in clinical practice.
Moreover, data sharing plays a critical role in refining genotype-phenotype associations. Collaborative platforms like ClinVar enable laboratories and researchers to pool evidence, improving the reliability of variant classifications.
Regular reanalysis of variants—especially those labeled as VUS—using updated data or advancements in functional studies can lead to reclassification, strengthening the accuracy of genotype-phenotype mapping.
Practical Tips for Effective Variant Interpretation
1. Collaborate with a Multidisciplinary Team
Collaboration across a multidisciplinary team is important for accurate and effective clinical variant interpretation. Geneticists, clinicians, and bioinformaticians each bring unique expertise to the process, ensuring that no critical detail is overlooked.
Geneticists contribute deep knowledge of variant function and inheritance patterns, while clinicians provide insights into patient histories and phenotypic presentations. Bioinformaticians, on the other hand, apply computational tools to analyze and interpret massive datasets. By combining these perspectives, you can approach variant classification more comprehensively, reducing the risk of misinterpretation.
Facilitating this teamwork requires robust systems for data sharing and integration. Tools like Euformatics’ Genomics Hub streamline collaboration by enabling seamless data exchange among team members. These platforms centralize variant data, annotations, and clinical context, making it easier to cross-reference findings and discuss interpretations efficiently. Centralized tools also help minimize errors that can arise from fragmented workflows, ensuring that everyone works from the same set of data.
2. Stay Updated with Advances
Keeping up with the rapid advancements in genomics is important for effective clinical variant interpretation. New variant databases, computational tools, and clinical guidelines are constantly evolving, and staying informed ensures that your analyses remain accurate and comprehensive. Regularly review updates to databases such as ClinVar, gnomAD, and HGMD, as they incorporate new evidence that can influence variant classification.
Familiarize yourself with improvements in computational tools that predict variant effects or streamline data analysis. Additionally, track updates to clinical guidelines from authoritative bodies like the American College of Medical Genetics (ACMG), as these often reflect the latest consensus on best practices.
Participating in external quality assessment (EQA) programs, such as those offered by EMQN and GenQA, is another critical strategy for maintaining high standards. These programs evaluate your laboratory’s performance against recognized benchmarks, providing insights into areas for improvement.
They also foster alignment with international standards, which is important for ensuring consistency in variant interpretation. Regular participation not only sharpens your skills but also demonstrates a commitment to delivering reliable and clinically actionable results.
3. Document and Communicate Findings Clearly
Maintaining clear documentation is critical for evidence-based variant classification. Every step of the interpretation process—data sources, computational predictions, clinical correlations, and laboratory findings—should be comprehensively recorded.
This ensures that the evidence underpinning a variant’s classification is transparent and reproducible. Well-documented cases also support re-evaluation as new information becomes available, which is especially important for variants of uncertain significance (VUS).
Beyond internal use, comprehensive documentation supports external reviews and audits, ensuring that laboratories meet accreditation standards and align with best practices.
Customizable reporting options offer significant advantages by addressing the diverse needs of clinicians, researchers, and patients. Laboratories should tailor reports to include the level of detail required by the intended audience. For example:
- Clinicians might prioritize concise summaries highlighting actionable findings and their clinical implications.
- Researchers might require detailed annotations, including allele frequencies, computational scores, and references to supporting studies.
- Patients benefit from simplified, jargon-free explanations that clarify the findings in a way they can understand.
Flexibility in reporting formats improves usability, ensuring that the information is not only accurate but also accessible and relevant to its recipients.
Conclusion
Clinical variant interpretation is both a precise science and a key element of personalized medicine. Its success relies on a combination of robust methodologies, interdisciplinary collaboration, and staying current with genomic advancements. By approaching it with rigor and clarity, practitioners can make informed decisions that directly improve patient outcomes.
To streamline clinical variant interpretation and ensure compliance with industry standards, Euformatics offers advanced solutions tailored to the needs of diagnostic laboratories and clinical research. Their Genomics Hub simplifies variant analysis with tools designed for accuracy and efficiency. Explore the transparent pricing configurator to customize your genomic service needs, or book a demo to see how Euformatics can enhance your workflows.
FAQ
What Is a Clinical Variant?
A genetic change in DNA that might affect health or disease. It guides diagnosis and personalized treatment by linking genetic data to medical care.
What Is a Variant of Clinical Significance?
A genetic alteration that may influence health, disease risk, or response to therapy, is classified based on evidence of its clinical impact.
What Are the Clinical Classification of Variants?
Variants are categorized as pathogenic, likely pathogenic, benign, likely benign, or uncertain significance (VUS) using ACMG guidelines.
What Does Variant Mean in Medical Terms?
A DNA change compared to a reference sequence. Variants may be harmless, harmful, or of unclear impact, influencing health and treatment.
How Do I Use ACMG/AMP Guidelines in Variant Interpretation?
Use the guidelines to classify variants into five tiers by evaluating population data, computational predictions, and clinical evidence for consistent and accurate results.
Reference
- Gudmundsson, Sanna, Moriel Singer‐Berk, Nicholas A. Watts, William Phu, Julia K. Goodrich, Matthew Solomonson, Genome Aggregation Database Consortium, Heidi L. Rehm, Daniel G. MacArthur, and Anne O’Donnell‐Luria. “Variant interpretation using population databases: Lessons from gnomAD.” Human mutation 43, no. 8 (2022): 1012-1030.
- Hecht, Maximilian, Yana Bromberg, and Burkhard Rost. “Better prediction of functional effects for sequence variants.” BMC genomics 16 (2015): 1-12.
- Niroula, Abhishek, and Mauno Vihinen. “Variation interpretation predictors: principles, types, performance, and choice.” Human mutation 37, no. 6 (2016): 579-597.
Rehder, Catherine, Lora JH Bean, David Bick, Elizabeth Chao, Wendy Chung, Soma Das, Julianne O’Daniel et al. “Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG).” Genetics in Medicine 23, no. 8 (2021): 1399-1415.
